...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >A Systems Pharmacology Approach for Identifying the Multiple Mechanisms of Action for the Rougui-Fuzi Herb Pair in the Treatment of Cardiocerebral Vascular Diseases
【24h】

A Systems Pharmacology Approach for Identifying the Multiple Mechanisms of Action for the Rougui-Fuzi Herb Pair in the Treatment of Cardiocerebral Vascular Diseases

机译:一种系统药理学方法,用于鉴定Rougui-Fuzi Herb对在血管血管疾病治疗中的多种作用机制

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Cardiocerebral vascular diseases (CCVDs) are the main reasons for high morbidity and mortality all over the world, including atherosclerosis, hypertension, myocardial infarction, stroke, and so on. Chinese herbs pair of the Cinnamomum cassia Presl (Chinese name, rougui) and the Aconitum carmichaelii Debx (Chinese name, fuzi) can be effective in CCVDs, which is recorded in the ancient classic book Shennong Bencao Jing, Mingyibielu and Thousand Golden Prescriptions. However, the active ingredients and the molecular mechanisms of rougui-fuzi in treatment of CCVDs are still unclear. This study was designed to apply a system pharmacology approach to reveal the molecular mechanisms of the rougui-fuzi anti-CCVDs. The 163 candidate compounds were retrieved from Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP). And 84 potential active compounds and the corresponding 42 targets were obtained from systematic model. The underlying mechanisms of the therapeutic effect for rougui-fuzi were investigated with gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Then, component-target-disease (C-T-D) and target-pathway (T-P) networks were constructed to further dissect the core pathways, potential targets, and active compounds in treatment of CCVDs for rougui-fuzi. We also constituted protein-protein in interaction (PPI) network by the reflect target protein of the crucial pathways against CCVDs. As a result, 21 key compounds, 8 key targets, and 3 key pathways were obtained for rougui-fuzi. Afterwards, molecular docking was performed to validate the reliability of the interactions between some compounds and their corresponding targets. Finally, UPLC-Q-Exactive-MSE and GC-MS/MS were analyzed to detect the active ingredients of rougui-fuzi. Our results may provide a new approach to clarify the molecular mechanisms of Chinese herb pair in treatment with CCVDs at a systematic level.
机译:心脏癌血管疾病(CC​​VDS)是全世界发病率和死亡率高的主要原因,包括动脉粥样硬化,高血压,心肌梗塞,中风等。中草药对Cinnamomum cassia presl(中文名,rougui)和aconitum carmichaelii debx(中文名称,富子)可以在CCVDS中生效,该CCVDS在古代经典书中记录了神农Bencao静,Mingyibielu和千金色的处方。然而,活性成分和Rougui-Fuzi治疗CCVDS的分子机制仍不清楚。本研究旨在应用系统药理学方法来揭示鲁富富子抗CCVDS的分子机制。从中药系统药理学数据库和分析平台(TCMSP)中检索163个候选化合物。和84个潜在的活性化合物和相应的42个靶标是从系统模型中获得的。 Rougui-Fuzi治疗效果的潜在机制是用基因本体学(GO)富集分析和基因和基因组(KEGG)途径富集分析的京都百科全书。然后,构建组分 - 靶向疾病(C-T-D)和靶途径(T-P)网络以进一步将核心途径,潜在靶标和活性化合物分析为Rougui-Fuzi的CCVDS。我们还通过对CCVDS的关键途径的反射靶蛋白构成蛋白质 - 蛋白质(PPI)网络。结果,为Rougui-Fuzi获得了21种关键化合物,8个关键靶标和3个关键途径。然后,进行分子对接以验证某些化合物与其相应靶之间的相互作用的可靠性。最后,分析了UPLC-Q-Exactive-MSE和GC-MS / MS检测Rougui-Fuzi的活性成分。我们的结果可以提供一种新方法,以澄清中草药对在系统水平下用CCVDS治疗的分子机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号